Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Gjettum – page 44

616 clinical trials in Gjettum, Norway across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Gjettum at a glance
616
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

616 trials in Gjettum

Open in trial search

Study of mRNA-4157 and Pembrolizumab for Patients with Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Study of Acalabrutinib for Patients with Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:AstraZeneca AB

Cervix carcinoma

Not recruiting

Study of Chemoradiotherapy With or Without Pembrolizumab for Patients With High-Risk, Locally Advanced Cervical Cancer

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Effectiveness of Enlicitide Chloride in Reducing Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Enlicitide decanoate
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Safety and Effectiveness of Bezuclastinib for Patients with Advanced Systemic Mastocytosis

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bezuclastinib
  • Sponsor:Cogent Biosciences Inc.

Study comparing stem cell transplantation versus alemtuzumab, cladribine or ocrelizumab in patients with aggressive relapsing-remitting multiple sclerosis

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Alemtuzumab
  • Sponsor:Helse Bergen HF

Plasma cell myeloma+1

Not recruiting

Study Comparing bb2121 with Standard Treatments for Patients with Relapsed and Refractory Multiple Myeloma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Study of Disitamab Vedotin and Pembrolizumab for Patients with Untreated Advanced Urothelial Cancer Expressing HER2

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Seagen Inc.

Study on the Effects of Obeticholic Acid and Bezafibrate for Patients with Primary Biliary Cholangitis Who Cannot Tolerate Ursodeoxycholic Acid

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bezafibrate
  • Sponsor:Intercept Pharmaceuticals Inc.

Hip fracture

Not recruiting

Study on Zoledronic Acid for Patients with Hip Fractures: Evaluating Early Treatment Safety and Effectiveness

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Zoledronic Acid
  • Sponsor:Oslo University Hospital HF

Asthma

Not recruiting

Study Comparing Depemokimab, Mepolizumab, and Benralizumab for Adults and Adolescents with Severe Eosinophilic Asthma

Registered drug
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study Comparing Injection Therapy with Triamcinolone Acetonide and Triamcinolone Hexacetonide to Surgery for Carpal Tunnel Syndrome in Adults

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Triamcinolone Acetonide
  • Sponsor:Diakonhjemmet Sykehus AS

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway

Clinical research in Gjettum

What the registry says about research in the country

01 Gastroenterology Research

Innovative trials focusing on inflammatory bowel diseases, including studies of combination therapies for both Crohn's Disease and Ulcerative Colitis. Research aims to evaluate new treatment approaches using targeted biological agents.

  • Crohn's Disease Management
  • Ulcerative Colitis Treatment
  • Combination Therapy Assessment

These studies explore dual-therapy approaches to improve clinical outcomes for patients with moderate to severe disease activity.

02 Cardiovascular Studies

Research focusing on prevention and treatment of stroke and cardiac conditions, including innovative approaches for managing atrial fibrillation and evaluating new anticoagulation therapies.

  • Stroke Prevention
  • Atrial Fibrillation Management
  • Thrombolysis Research

Trials aim to improve outcomes in acute ischemic stroke and prevent cardiac complications.

03 Musculoskeletal Medicine

Comprehensive research into orthopedic conditions, including studies on osteoarthritis, carpal tunnel syndrome, and hip fracture treatments.

  • Joint Disease Management
  • Surgical vs. Conservative Treatment
  • Post-fracture Care

Investigations compare different treatment approaches and timing of interventions for optimal patient outcomes.

04 Infectious Disease Research

Studies addressing various infectious conditions including COVID-19 and mpox, evaluating novel therapeutic approaches and treatment strategies.

  • COVID-19 Treatment Trials
  • Mpox Management
  • Antiviral Therapy Assessment

Research focuses on understanding disease progression and testing new therapeutic interventions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.